已发表论文

接受新辅助化疗和乳房切除术治疗 II-III 期三阴性乳腺癌患者在乳房切除术后进行放疗可减少局部复发和疾病复发

 

Authors Chen XX, Xia F, Luo JR, Ma JL, Yang ZZ, Zhang L, Feng Y, Shao ZM, Yu XL, Guo XM

Received 30 November 2017

Accepted for publication 10 February 2018

Published 5 April 2018 Volume 2018:11 Pages 1973—1980

DOI https://doi.org/10.2147/OTT.S158482

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 5

Editor who approved publication: Dr Carlos Vigil Gonzales

Background: This study investigated the effect of postmastectomy radiotherapy (PMRT) in patients with stage II–III triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NAC) and modified radical mastectomy (MRM).
Patients and methods: A total of 104 women with stage II–III TNBC who received NAC and MRM at our institution between January 2000 and July 2007 were identified. Patients were divided into 2 groups (PMRT and non-PMRT) for statistical analysis.
Results: The median follow-up time was 64 months (range 12–123 months). The 5 year cumulative locoregional recurrence (LRR) and disease recurrence (DR) rates were 26.5% and 49.6%, respectively. Despite their more adverse prognostic features, patients with PMRT had lower 5 year cumulative LRR and DR rates than those without PMRT (LRR: 18.3% vs 52.2%, respectively, =0.0005; DR: 45% vs 69.1%, =0.0334, respectively). On multivariate analysis of the entire study cohort, forgoing PMRT was significantly associated with developing LRR and DR. Subset analysis revealed that PMRT significantly reduced the 5 year LRR rate in patients with pre-chemotherapy clinical stages IIA (8.3% vs 46.2%, =0.019) and IIIA (16% vs 66.7%, =0.003). PMRT also significantly reduced the 5 year DR rate in patients with pre-chemotherapy clinical stage IIA (24.5% vs 69.3%, =0.0151) and ≥IIIB (70.8% vs 100%, =0.0481).
Conclusion: In our cohort of patients with TNBC treated with NAC and MRM, PMRT significantly improved locoregional control and disease-free survival in the entire cohort as well as in patients with stage IIA disease. Our results may help in tailoring adjuvant treatment decisions for these particular patient populations.
Keywords: triple-negative breast carcinoma, neoadjuvant chemotherapy, surgery, adjuvant radiation therapy, locoregional recurrence, disease recurrence